Author:
Song Pei-ran,Wan Zhi-peng,Huang Ge-ge,Song Zi-lan,Zhang Tao,Tong Lin-jiang,Fang Yan,Tang Hao-tian,Xue Yu,Zhan Zheng-sheng,Feng Fang,Li Yan,Shi Wen-hao,Huang Yu-qing,Chen Yi,Duan Wen-hu,Ding Jian,Zhang Ao,Xie Hua
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310.
2. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.
3. Kuo HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, Wu S, et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016;6:2489–501.
4. Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, et al. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study. Blood Adv. 2023;7:7459–70.
5. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.